# Progress Note 01 — Initial plan

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Calamity Jane (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-NI008-SYN-TD
- Date: 1901-03-02
- Fictional facility: St. Posthumous Health Center
- Fictional author: Ruth Ann Kessler, MD
- Calendar frame: true historical dates (modern content is anachronistic)

> True-date frame: synthetic events are moved into the patient's historical lifetime. Codes, instruments, and treatments remain modern and are anachronistic.

## Subjective

The patient participates in this fictional visit for establishing primary care for heavy daily drinking: a nonjudgmental, trauma-informed assessment, withdrawal risk and outpatient withdrawal management, thiamine, liver tests, nutrition, mood and safety, and housing, food and income. **S**

## Objective

White blood cells: 6.8 10*3/uL; Hemoglobin: 12.1 g/dL; MCV: 103 fL (high); Platelets: 162 10*3/uL; Sodium: 134 mmol/L (low); Potassium: 3.3 mmol/L (low); Creatinine: 0.62 mg/dL; eGFR (CKD-EPI 1896): 113 mL/min/1.73 m²; Glucose: 78 mg/dL; Magnesium: 1.5 mg/dL (low); Phosphate: 2.4 mg/dL (low); Albumin: 3.4 g/dL (low); Total bilirubin: 1.1 mg/dL; INR: 1; AST: 96 U/L (high); ALT: 44 U/L (high); GGT: 240 U/L (high); Folate: 3.2 ng/mL (low); Vitamin B12: 410 pg/mL; PEth: 820 ng/mL (high); AUDIT: 31; PHQ-9: 14; GAD-7: 11; PC-PTSD-5: 2. All results are synthetic.

BP 146/92 mmHg; pulse 104 bpm; respirations 18/min; temperature 37.2 °C; oxygen saturation 97% on room air; weight 50 kg; BMI 18.4 kg/m². All vital signs are synthetic.

## Assessment

Active problems: Alcohol use disorder, severe (nine of eleven DSM-5-TR criteria), daily drinking of about a pint of whiskey with heavier binges for many years; synthetic modern episode linked to her documented lifelong heavy drinking; Alcohol withdrawal, mild, at low risk of complications (PAWSS 3, CIWA-Ar 9 at intake; no past seizures or delirium tremens), managed as an outpatient with daily nurse checks; Raised liver enzymes (AST 96, ALT 44, GGT 240 U/L) with a FIB-4 index of 3.93, above the cut point for possible advanced fibrosis; liver stiffness measurement planned; Depressive symptoms during heavy drinking (PHQ-9 14, item 9 scored 0); whether they are alcohol-induced or an independent depression to be judged after two to four weeks without alcohol; Daily chewing tobacco for many years; not ready to stop at intake; Underweight (BMI 18.4) with poor food intake, low folate, magnesium and phosphate, and slightly low albumin; Housing instability: staying in a spare room at a friend's house, with nowhere to go if that ends; has stayed in shelters in past winters; Food insecurity: often goes without meals at the end of the month. Strengths and supports remain part of the care plan. **S**

## Medication changes

- Started: Gabapentin 300 mg oral capsule on a written five-day schedule for alcohol withdrawal: 300 mg in the morning, 300 mg in the afternoon and 600 mg at bedtime for three days, then 300 mg twice daily on day four, 300 mg at bedtime on day five, then stop; dispensed for the five days only **S**
- Started: Thiamine 100 mg by intramuscular injection once daily for three days, given in the clinic **S**
- Started: Folic acid 1 mg oral tablet, one tablet daily **S**
- Started: Potassium chloride extended-release 20 mEq oral tablet, one tablet daily with food for five days **S**
- Started: Magnesium oxide 400 mg oral tablet, one tablet twice daily for two weeks **S**

## Plan

- A nonjudgmental, trauma-informed assessment: AUDIT, DSM-5-TR criteria and PEth explained as part of care, person-first language, a female clinician and a chaperone offered, consent asked before each part of the examination, and her own goals and choices first. Guideline: The American Psychiatric Association Practice Guideline for the Pharmacological Treatment of Patients With Alcohol Use Disorder (2018); The Healthcare Professional's Core Resource on Alcohol (2026); Unhealthy Alcohol Use in Adolescents and Adults: Screening and Behavioral Counseling Interventions (2018) **S**
- Addiction medicine consultation to confirm the diagnosis, review withdrawal and choose a medicine for alcohol use disorder. Guideline: The American Psychiatric Association Practice Guideline for the Pharmacological Treatment of Patients With Alcohol Use Disorder (2018); The ASAM Clinical Practice Guideline on Alcohol Withdrawal Management (2020) **S**
- Outpatient withdrawal management at low risk (PAWSS 3, CIWA-Ar 9): a five-day gabapentin schedule, daily nurse checks with the CIWA-Ar in person or by the clinic phone, her friend as support, fluids and food; hospital care at once for a CIWA-Ar of 15 or more, a seizure, hallucinations, confusion or vomiting. Guideline: The ASAM Clinical Practice Guideline on Alcohol Withdrawal Management (2020) **S**
- Thiamine 100 mg by injection for three days, then by mouth, with folic acid, potassium and magnesium replacement. Guideline: The ASAM Clinical Practice Guideline on Alcohol Withdrawal Management (2020); Diagnosis and Treatment of Alcohol-Associated Liver Diseases: 2019 Practice Guidance From the American Association for the Study of Liver Diseases (2019) **S**
- Liver: FIB-4 of 3.93, so transient elastography; liver enzymes, albumin, INR and platelets followed; hepatitis A and B vaccination; acetaminophen no more than 2 g a day. Guideline: Diagnosis and Treatment of Alcohol-Associated Liver Diseases: 2019 Practice Guidance From the American Association for the Study of Liver Diseases (2019) **S**
- Mood and safety: PHQ-9 and GAD-7 again after two to four weeks without alcohol before deciding on depression treatment; a structured safety assessment, a written safety plan, the rifle stored with her friend, the 988 Suicide & Crisis Lifeline, and safety review at every visit. Guideline: The American Psychiatric Association Practice Guideline for the Pharmacological Treatment of Patients With Alcohol Use Disorder (2018); Depression and Suicide Risk in Adults: Screening (2023); VA/DoD Clinical Practice Guideline for Assessment and Management of Patients at Risk for Suicide (2024); CMID: Clinical Monitoring Intelligence Database, depression, bipolar, and mood disorders monograph (2026) **S**
- Recovery support and harm reduction: weekly contact with the clinic's peer recovery support specialist, her choice of mutual-help meetings (Alcoholics Anonymous, SMART Recovery or Women for Sobriety), and a plan for a return to drinking: call the peer specialist or the clinic, eat, do not drink alone or drive, keep taking any medicine for alcohol use disorder, and come back without shame. Guideline: The American Psychiatric Association Practice Guideline for the Pharmacological Treatment of Patients With Alcohol Use Disorder (2018); The Healthcare Professional's Core Resource on Alcohol (2026) **S**
- Housing, food, income and coverage: the clinic's community health worker helps with a Montana Medicaid application, SNAP benefits, a food bank, the local Human Resource Development Council's housing programs, Montana 211, and a free phone through the Lifeline program. Guideline: The Healthcare Professional's Core Resource on Alcohol (2026) **S**
- Alcohol and women's health: why the same amount of alcohol does women more harm (higher blood alcohol, faster liver damage, a higher breast cancer risk), a pregnancy test, contraception if needed, and breast and cervical cancer screening at the preventive visit. Guideline: The Healthcare Professional's Core Resource on Alcohol (2026) **S**
- Chewing tobacco: advice to stop and nicotine replacement offered whenever she is ready. Guideline: Tobacco Smoking Cessation in Adults, Including Pregnant Persons: Interventions (2021) **S**
